HELP

Cybin Inc.

12.19 USD

Last updated Sep 4, 20:57 UTC

Yesterday HIGH

$12

Yesterday LOW

$11.39

52w HIGH

$14.35

52w LOW

$3.76

EPS

-0.91

PE

-13.40

Next Earnings

Nov 12, 2026

Overview News Unusual Options Flow Government Trades Fundamentals

Cybin Inc. stock is up 15.76% since 30 days ago. The next earnings date is Nov 12, 2026. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 20% of the previous 5 September’s closed higher than August. In the last 10 Unusual Options Trades, there were 9 CALLs, 1 PUT. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time	Expiration Date	Strike Price	Trade Type	Size	Open Interest

14 Aug 19:46	15 Jan, 2027	15.00	CALL	200	244
14 Aug 19:46	19 Mar, 2027	12.50	CALL	50	293
14 Aug 19:49	18 Dec, 2026	10.00	CALL	87	8495
18 Aug 14:54	18 Dec, 2026	10.00	CALL	100	8488
18 Aug 18:33	20 Nov, 2026	12.50	CALL	120	242
21 Aug 15:15	16 Oct, 2026	12.50	CALL	100	52
24 Aug 17:54	15 Jan, 2027	15.00	CALL	199	666
24 Aug 18:02	18 Dec, 2026	20.00	CALL	2000	168
27 Aug 18:53	18 Dec, 2026	15.00	PUT	50	3
31 Aug 13:39	18 Dec, 2026	5.00	CALL	48	1383

Advanced Data Unlock

Avi Kapoor

Thu Jul 16, 2026

Why JB Hunt Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket

JB Hunt Transport Services Inc (JBHT) beat earnings and revenue estimates, causing shares to surge 7.9% in pre-market trading. Other top gainers include ATPC, TGHL, ATAI, DXST, KAPA, EHGO, HELP, VSA, and CMPS.
Benzinga Newsdesk

Thu Jul 9, 2026

HC Wainwright & Co. Maintains Buy on Helus Pharma, Lowers Price Target to $70

HC Wainwright & Co. analyst Patrick R. Trucchio maintains Helus Pharma (NASDAQ:HELP) with a Buy and lowers the price target from $95 to $70.
Benzinga Newsdesk

Wed Jul 1, 2026

Canaccord Genuity Maintains Buy on Helus Pharma, Lowers Price Target to $42

Canaccord Genuity analyst Sumant Kulkarni maintains Helus Pharma (NASDAQ:HELP) with a Buy and lowers the price target from $45 to $42.
Benzinga Newsdesk

Mon Jun 29, 2026

Helus Pharma Q4 EPS $(0.85) Beats $(1.11) Estimate

Helus Pharma (NASDAQ:HELP) reported quarterly losses of $(0.85) per share which beat the analyst consensus estimate of $(1.11) by 23.42 percent. This is a 16.67 percent increase over losses of $(1.02) per share from the
Benzinga Newsdesk

Thu Jun 25, 2026

Helus Pharma shares are trading higher. The company announced the closing of its $50 million underwritten offering.
Benzinga Insights

Thu Jun 25, 2026

12 Health Care Stocks Moving In Thursday's Intraday Session

Gainers Atlantic International (NASDAQ:ATLN) shares increased by 41.0% to $1.1 during Thursday's regular session. The company's market cap stands at $59.4 million. As per the press release, Q1 earnings came out
Benzinga Newsdesk

Wed Jun 24, 2026

Helus Pharma Prices Underwritten Offering Of 10.3M Shares At $4.85 Per Share; Announces That Enrollment In The APPROACH Phase 3 Clinical Trial Of HLP003 For Adjunctive Treatment Of Major Depressive Disorder Is Progressing As Planned, Surpassing 86% Enrollment

- APPROACH Phase 3 clinical trial of HLP003 for the adjunctive treatment of major depressive disorder ("MDD") is progressing as planned and has surpassed 86% enrollment -- Phase 2 HLP003 data demonstrated
Benzinga Newsdesk

Fri May 8, 2026

'Health Officials Close To U.S. Secretary Kennedy Explored Ban Of Some Widely Used Antidepressants' - Reuters Exclusive

Health officials explored restricting specific antidepressants among SSRI drugs-sources
Benzinga Newsdesk

Mon Apr 20, 2026

Helus Pharma CEO Michael Cola Stepping Down, Effective Immediately; Executive Chairman Eric So Appointed Interim CEO

Helus Pharma™ (Nasdaq: HELP) (Cboe CA: HELP), a clinical stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists ("NSAs"), today announced that Michael Cola is
Benzinga Newsdesk

Mon Apr 13, 2026

TD Cowen Initiates Coverage On Helus Pharma with Buy Rating, Announces Price Target of $8

TD Cowen analyst Ritu Baral initiates coverage on Helus Pharma (NASDAQ:HELP) with a Buy rating and announces Price Target of $8.